Bempedoic acid — The Non-Statin Cholesterol Lowerer
Bempedoic acid is a novel, non-statin lipid-lowering drug that reduces LDL cholesterol by inhibiting ATP-citrate lyase in the liver. Because it is not activated in skeletal muscle, it offers a crucial alternative for patients with statin intolerance, helping to mitigate cardiovascular risk and promote longevity in those unable to achieve lipid targets with traditional therapies.
Mechanism of Action
Bempedoic acid is a first-in-class, oral, small-molecule inhibitor of ATP-citrate lyase (ACL), an enzyme upstream of HMG-CoA reductase in the cholesterol biosynthesis pathway. By inhibiting ACL, it reduces cholesterol synthesis in the liver, which leads to the upregulation of LDL receptors and increased clearance of LDL cholesterol from the blood. Crucially, bempedoic acid is a prodrug that requires activation by very-long-chain acyl-CoA synthetase 1 (ACSVL1), an enzyme present in the liver but absent in skeletal muscle. This liver-specific activation prevents the muscle-related adverse effects commonly associated with statins.
Human Trial Evidence
Bempedoic acid has been extensively studied in humans, most notably in the CLEAR Outcomes trial. In this trial involving over 13,000 statin-intolerant patients, bempedoic acid significantly reduced the risk of major adverse cardiovascular events (MACE) compared to placebo. It effectively lowers LDL cholesterol by approximately 15-25% as a monotherapy and is often used when statins are not tolerated or insufficient.
Dosing Protocol
180 mg once daily, taken orally with or without food. It is a prescription-only medication. Dose adjustment is not typically required for mild-to-moderate renal or hepatic impairment.
Safety & Contraindications
Common adverse effects include hyperuricemia, which can precipitate gout, and an increased risk of tendon rupture. It is contraindicated in patients with a history of severe gout or tendon rupture. Bempedoic acid can interact with simvastatin and pravastatin, increasing their plasma concentrations and the risk of myopathy, so dose limits for these statins are recommended when co-administered. It is a prescription-only medication.